Drugs used to enhance sexual experiences

Drugs used to enhance sexual experiences


The findings, published today in The Journal of Sexual Medicine, revealed that alcohol, cannabis, MDMA and cocaine are the drugs most commonly combined with sex.To get more news about buy vigrx plus, you can visit vigrxplus-original.com official website.

Respondents from the United Kingdom were the most likely to combine drugs with sex, compared with the US, other European countries, Australia and Canada.
“While using drugs in combination with and to specifically enhance the sexual experience tends to be associated with gay and bisexual men, we found that in our sample, men and women of all sexual orientations engaged in this behaviour. However, differences between groups did emerge,” said the study’s lead author, Dr Will Lawn (UCL Psychology & Language Sciences).

“Harm reduction messages relating to substance-linked sex in general should therefore not only be targeted towards gay and bisexual men, as they are relevant to all groups.”

As part of the Global Drug Survey, roughly 22,000 people responded to online questions about which drugs they used in combination with sex, in addition to questions about whether they used drugs to specifically enhance their sexual experience, and how these drugs affect the sexual experience.

Alcohol, cannabis, MDMA and cocaine were most commonly used, while GHB/GBL and MDMA were rated most favourably. For instance, MDMA increased ‘emotionality/intimacy’ the most, while GHB/GBL increased ‘sexual desire’ the most.

While people of all genders and sexual orientations reported engaging in substance-linked sex, gay and bisexual men were more likely to have done so; homosexual men were 1.6 times as likely as heterosexual men to have used drugs with the specific intent of enhancing the sexual experience in the last year.

Drugs typically considered as ‘chemsex’ drugs – methamphetamine, mephedrone and GHB/GBL – were more commonly used by gay and bisexual men in combination with sex, which the researchers say highlights the continued need for certain targeted harm reduction messages.

As the survey respondents were self-selecting rather than a representative sample, the researchers say their estimates of prevalence will be substantially larger than the general population. However, relative differences between groups are expected to be reliable.

While country of residence was not asked specifically, currency was used as a proxy. This revealed that those from the UK were more likely to have combined all drugs, except for cannabis, with sex; this trend was particularly strong for mephedrone.

The researchers say that understanding how and why people use drugs is essential if we are to deliver harm reduction messages that are in touch with peoples’ lived experience.

“By engaging with your audience and accepting that drugs provide pleasure as well as harms, you can deliver harm reduction messages in a more trustworthy and nuanced manner,” said Dr Lawn.